Top Markets
Coin of the day
CARGO Therapeutics, Inc. Common Stock CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock

CRGX
Rank in Stocks #18093
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company... CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
Share Price
$4.47
Last synced: 2025-08-20
Market Cap
$213.06M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade CARGO Therapeutics, Inc. Common Stock (CRGX)

Category

P/B ratio for CARGO Therapeutics, Inc. Common Stock (CRGX)
P/B ratio as of 2026 TTM: 0
According to CARGO Therapeutics, Inc. Common Stock latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for CARGO Therapeutics, Inc. Common Stock from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH